Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 60 Leukemia 32 Gastrointestinal Stromal Tumors 27 Precursor Cell Lymphoblastic Leukemia-Lymphoma 21 Leukemia, Myeloid, Chronic-Phase 21 Blast Crisis 9 Philadelphia Chromosome 8 Neoplasm Metastasis 8 Melanoma 8 Lung Neoplasms 8 Brain Neoplasms 7 Sarcoma 6 Prostatic Neoplasms 6 Neoplasms 6 Recurrence 5 Ovarian Neoplasms 5 Glioblastoma 5 Carcinoma, Non-Small-Cell Lung 5 Small Cell Lung Carcinoma 4 Primary Myelofibrosis 4 Polycythemia Vera 4 Leukemia, Myelomonocytic, Chronic 4 Leukemia, Myeloid, Acute 4 Leukemia, Myeloid, Accelerated Phase 4 Leukemia, Myeloid 4 Dermatofibrosarcoma 4 Carcinoma, Ovarian Epithelial 4 Breast Neoplasms 4 Osteosarcoma 3 Neuroectodermal Tumors, Primitive, Peripheral 3

Interventions

trametinib 1 dabrafenib 1 Imatinib Mesylate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Rare Malignant Neoplasm × Imatinib Mesylate × Clear all

NCT06119789 2025-03-26

MATRIX-Rare

Oslo University Hospital

Phase 2 Recruiting

Rare Malignant Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon ⚡